Amicus Stockholders Approve BioMarin Acquisition at Special Meeting

Amicus ( (FOLD) ) just unveiled an announcement.

On March 3, 2026, stockholders of Amicus Therapeutics approved the company’s acquisition by BioMarin Pharmaceutical, with approximately 74.79% of eligible shares represented at a special virtual meeting and an overwhelming majority voting in favor of the merger agreement. Shareholders also backed, on an advisory basis, the merger-related executive compensation package, and with stockholder approval and early termination of the U.S. Hart-Scott-Rodino waiting period granted on February 11, 2026, the transaction now depends on remaining regulatory clearances, including in certain European jurisdictions and Japan, and is expected to close in the second quarter of 2026, potentially reshaping Amicus’s ownership structure and integration into BioMarin’s rare-disease portfolio.

The most recent analyst rating on (FOLD) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Amicus stock, see the FOLD Stock Forecast page.

Spark’s Take on FOLD Stock

According to Spark, TipRanks’ AI Analyst, FOLD is a Neutral.

The score is driven primarily by improving financial trajectory (notably the shift to positive operating/free cash flow) but tempered by still-elevated leverage and uneven profitability. Technicals are supportive yet overbought, valuation is weak due to negative earnings and no dividend, while the earnings outlook and the announced all-cash acquisition meaningfully improve near-term visibility.

To see Spark’s full report on FOLD stock, click here.

More about Amicus

Amicus Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. Operating in the U.S. and global markets, it targets specialized patient populations with high unmet medical need, positioning itself within the competitive rare-disease and genetic-disorder treatment segment of the pharmaceutical industry.

Average Trading Volume: 11,068,570

Technical Sentiment Signal: Buy

Current Market Cap: $4.51B

For detailed information about FOLD stock, go to TipRanks’ Stock Analysis page.